Study to Evaluate the Safety and Immunogenicity of KBP-V001 Quadrivalent Influenza Vaccine in Healthy Adults
A Phase 1, Observer-blinded, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Safety and Immunogenicity of KBP-V001 Quadrivalent Influenza Vaccine in Healthy Adults
Sponsor: KBio Inc
A PHASE1 clinical study on Influenza, this trial is completed. The trial is conducted by KBio Inc and has accumulated 11 data snapshots since 2020. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Nov 2022 — Jul 2024 [monthly]
Completed PHASE1
-
Oct 2021 — Nov 2022 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Sep 2021 — Oct 2021 [monthly]
Active Not Recruiting PHASE1
▶ Show 6 earlier versions
-
May 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE1
-
Mar 2021 — May 2021 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Feb 2021 — Mar 2021 [monthly]
Recruiting PHASE1
-
Jan 2021 — Feb 2021 [monthly]
Recruiting PHASE1
-
Oct 2020 — Jan 2021 [monthly]
Recruiting PHASE1
-
Jul 2020 — Oct 2020 [monthly]
Recruiting PHASE1
First recorded
Jun 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- KBio Inc
For direct contact, visit the study record on ClinicalTrials.gov .